Replies to post #33463 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Mp, re-read the press release. There was no statement about looking at the data then deciding to termite it. All that was said is the following:

As part of its portfolio refinement, the company has determined it will not pursue further clinical study of ADXS-HER2 at this time, but remains open to ISTs or licensing opportunities.